Ligand Pharma Inc Roche Contingent Value Rights (LGNDZ)

[TREND1]

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2015, and provided an operating forecast and program updates.

Financial highlights for the second quarter of 2015 include:
• Total revenues were $18.4 million and royalty revenues were $6.6 million, an increase of 74% and 26%, respectively, compared with the second quarter of 2014.
• Adjusted EPS was $1.81 and GAAP EPS was $1.11.
• The company generated operating cash of $17.6 million, a significant increase over $6.6 million of operating cash generated in the second quarter of 2014.